Advertisement


Maria Svensson, MD, PhD Candidate, on Esophageal and Gastric Cancers: Significance of PD-1 and PD-L1 Expression

2018 Gastrointestinal Cancers Symposium

Advertisement

Maria Svensson, MD, PhD Candidate, of Lund University, discusses high expression of PD-1 and PD-L1 in chemotherapy-naive esophageal and gastric adenocarcinomas, the implications for survival, and the link to a deficiency in mismatched repair genes (Abstract 9).



Related Videos

Pancreatic Cancer
Immunotherapy

Steven D. Leach, MD, on Pancreatic Cancer: Keynote Lecture

Steven D. Leach, MD, of Dartmouth University’s Norris Cotton Cancer Center, discusses the personalized approach that GI cancers will require to make rational use of immunotherapy—i...

Gastroesophageal Cancer

Basem Azab, MD, on Esophageal Cancer: Study Survival Results

Basem Azab, MD, of the Sylvester Comprehensive Cancer Center, University of Miami, discusses the impact on overall survival when more than 2 months elapse between finishing neoadju...

Pancreatic Cancer

Kyaw L. Aung, MBBS, PhD, on Pancreatic Cancer: Results From the COMPASS Trial

Kyaw L. Aung, MBBS, PhD, of Princess Margaret Cancer Centre, discusses early study findings on genomics-driven precision medicine for advanced pancreatic ductal carcinoma (Abstract...

Gastrointestinal Cancer
Immunotherapy

Florian Lordick, MD, on Gastric Cancer: Final Results From the AIO Trial

Florian Lordick, MD, of the University Medicine Leipzig, discusses study findings on intraperitoneal immunotherapy with the antibody catumaxomab for patients with peritoneal carcin...

Colorectal Cancer
Immunotherapy

Thierry André, MD, and Michael J. Overman, MD, on Colorectal Cancer: Results From Two CheckMate-142 Trials

Thierry André, MD, of Hôpital Saint-Antoine, and Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from their respecti...

Advertisement

Advertisement



;
Advertisement